Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model.
By J. Fernández-Gómez, R. Madero, E. Solsona, M. Unda, L. Martínez-Piñeiro, Marcelino González, J. Portillo, A. Ojea, C. Pertusa, J. Rodríguez-Molina and 9 more. Journal of Urology, 2009
645 citations recorded by the source corpus.
PURPOSE Bacillus Calmette-Guerin is the most effective therapy for nonmuscle invasive bladder cancer. Recently to calculate the risks of recurrence and progression based on data from 7 European Organisation for Research and Treatment of Cancer trials a scoring system was reported. However, in that series only 171 patients were treated with bacillus Calmette-Guerin. We developed a risk stratification model to provide accurate estimates of recurrence and progression probability after bacillus Calmette-Guerin. MATERIALS AND METHODS Data were analyzed on 1,062 patients treated with bacillus Calmette-Guerin and included in 4 Spanish Urological Club for Oncological Treatment trials. Stepwise multivariate Cox models were used to determine the effect of prognostic factors. In each patient the weight of all factors was summed to a total score. Patients were then divided into groups, and cumulative recurrence and progression rates were calculated. RESULTS A scoring system was calculated with a score of 0 to 16 for recurrence and 0 to 14 for progression. Patients were categorized into 4 groups by score, and recurrence and progression probabilities were calculated in each group. For recurrence the variables were gender, age, grade, tumor status, multiplicity and associated Tis. For progression the variables were age, grade, tumor status, T category, multiplicity and associated Tis. For recurrence calculated risks using Spanish Urological Club for Oncological Treatment tables were lower than those obtained with Sylvester tables. For progression probabilities were lower in our model only in patients with high risk tumors. CONCLUSIONS We propose a scoring model to stratify the risk of recurrence and progression in patients treated with bacillus Calmette-Guerin.
Subfields: Biotechnology, Epidemiology, Surgery
View Paper: https://www.semanticscholar.org/paper/77d9252e3e54f8149770c1e2d212bc1f4e888353
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Surgery
Citations in the corpus
- European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ). (2021, background): “For progression, probability is lower only for high-risk patients [73] (LE: 2a).”
- EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. (2017, background): “The incidence and mortality of BCa has decreased in some registries, possibly reflecting the decreased impact of causative agents [3].”
- European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update. (2019, background): “Detection of concurrent CIS increases the risk of recurrence and progression of TaT1 tumours [62,64]; in this case, further treatment according to the criteria summarised in sections 3.”
- EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. (2013, background): “These are patients with the following characteristics [41,54,55] (LE: 3):”